Evidence map›Paper›PMID 40825055›Full record

ArticlePLoS computational biology2025

Mechanistic computational modeling of sFLT1 secretion dynamics.

Amy Gill, Karina Kinghorn, Victoria L Bautch, Feilim Mac Gabhann

Abstract read
In one paragraph

Article in PLoS computational biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Amy GillInstitute for Computational Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America.ORCID 0000-0003-0436-8390
Karina KinghornDepartment of Biology, University of North Carolina, Chapel Hill, North Carolina, United States of America.ORCID 0000-0002-2736-220X
Victoria L BautchDepartment of Biology, University of North Carolina, Chapel Hill, North Carolina, United States of America.ORCID 0000-0003-2135-5153
Feilim Mac GabhannInstitute for Computational Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America.ORCID 0000-0003-3481-7740

Funding

Systems Biology of Angiogenesis in Peripheral Arterial DiseaseR01HL101200 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI POPEL, ALEKSANDER S. · 2010 to 2022
$10.7M
MOLECULAR AND CELLULAR CONTROL OF ANGIOGENESISR35HL139950 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BAUTCH, VICTORIA L · 2018 to 2024
$6.4M
New Roles for VEGFR1 in AngiogenesisR01GM129074 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI MAC GABHANN, FEILIM C · 2018 to 2021
$2.6M
NHLBI NIH HHS R01 HL101200NHLBI NIH HHS R35 HL139950NIGMS NIH HHS R01 GM129074
6 · The paper itself

Abstract

Constitutively secreted by endothelial cells, soluble FLT1 (sFLT1 or sVEGFR1) binds and sequesters extracellular vascular endothelial growth factors (VEGF), thereby reducing VEGF binding to VEGF receptor tyrosine kinases and their downstream signaling. In doing so, sFLT1 plays an important role in vascular development and in the patterning of new blood vessels in angiogenesis. Here, we develop multiple mechanistic models of sFLT1 secretion and identify a minimal mechanistic model that recapitulates key qualitative and quantitative features of temporal experimental datasets of sFLT1 secretion from multiple studies. We show that the experimental data on sFLT1 secretion is best represented by a delay differential equation (DDE) system including a maturation term, reflecting the time required between synthesis and secretion. Using optimization to identify appropriate values for the key mechanistic parameters in the model, we show that two model parameters (extracellular degradation rate constant and maturation time) are very strongly constrained by the experimental data, and that the remaining parameters are related by two strongly constrained constants. Thus, only one degree of freedom remains, and measurements of the intracellular levels of sFLT1 would fix the remaining parameters. Comparison between simulation predictions and additional experimental data of the outcomes of chemical inhibitors and genetic perturbations suggest that intermediate values of the secretion rate constant best match the simulation with experiments, which would completely constrain the model. However, some of the inhibitors tested produce results that cannot be reproduced by the model simulations, suggesting that additional mechanisms not included here are required to explain those inhibitors. Overall, the model reproduces most available experimental data and suggests targets for further quantitative investigation of the sFLT1 system.

Indexed as

Models, BiologicalVascular Endothelial Growth Factor Receptor-1Computational BiologyComputer SimulationEndothelial CellsHumansSignal TransductionVascular Endothelial Growth Factor AFLT1 protein, humanVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-1

Identifiers

PMID40825055
PMCPMC12370208

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.